CLAIMS

1. A compound represented by formula (1):

[Formula 1]



(1)

wherein

R^1, R^2 and R^5 are each independently selected from a hydrogen atom, a halogen atom, a C_1-C_6 alkyl group which may be substituted with one or more halogen atoms and a C_1-C_6 alkoxy group which may be substituted with one or more halogen atoms;

R^3 and R^4 are each independently selected from a hydrogen atom, a halogen atom, -NRfRg, -CONRfRg, -CH=NORe, a C_1-C_6 alkoxy group, a C_1-C_6 alkyl group and -T-$(CH_2)_k$-V, wherein the alkyl group and the alkoxy group may be substituted with one or more substituents selected from a hydroxyl group, a C_1-C_6 alkoxy group, a halogen atom and -NRfRg;

wherein

Re is selected from a hydrogen atom and C_1-C_6 alkyl, wherein the alkyl group may be substituted with one to three substituents selected from a hydroxyl group, a C_1-C_6 alkoxy group, a halogen atom and -NRhRi,

Rf and Rg are each independently selected from a hydrogen atom, C_1-C_6 alkyl group and C_1-C_6

alkylcarbonyl group, wherein the alkyl group and the alkylcarbonyl group may be substituted with one to three substituents selected from a hydroxyl group, a C_1-C_6 alkoxy group, a halogen atom and -NRhRi,

Rh and Ri are each independently selected from a hydrogen atom and C_1-C_6 alkyl group, wherein the alkyl group may be substituted with one to three substituents selected from a hydroxyl group, a halogen atom and a C_1-C_6 alkoxy group, or

Rf and Rg, and Rh and Ri together with a nitrogen atom to which they are attached may form a 4- to 7-heterocycle, wherein the heterocycle may be substituted with a C_1-C_6 alkyl group,

T is an oxygen atom or a single bond; k is an integer selected from 0 to 4;

V is a 5- to 6-membered heterocyclyl group which may be substituted with one or more Y^3, -NRaRb, -CONRaRb, -OC(=O)NRaRb, -SO_2NRaRb, -N(-Ra)C(=O)NRa'Rb', -N(-Ra)C(=O)ORd, -C(=O)ORd, -$S(=O)_m$-Rd, -O-Rd, -OC(=O)Rc, -N(-Ra)C(=O)Rc, -N(Ra)SO_2Rc, -C(=NRa)NRa'Rb', -C(=NORa)Rc or -C(=O)Rc;

R^6 and R^7 are each independently selected from a hydrogen atom and a halogen atom;

Z^1 and Z^2 are each independently selected from a hydrogen atom, a hydroxyl group and -$O(CHR^{11})OC(=O)R^{12}$;

wherein

R^{11} is a hydrogen atom or a C_1-C_6 alkyl group;

R^{12} is a pyrrolidinyl group, a piperidinyl group, a morpholinyl group, a piperazinyl group, an amino C_1-C_6 alkyl group, a mono- or di(C_1-C_6 alkyl)amino C_1-C_6 alkyl group, an amino C_1-C_6 alkylamino group or a mono- or di(C_1-C_6 alkyl)-amino C_1-C_6 alkylamino group;

Q is a group of the formula:

[Formula 2]



wherein

G^1 is C-Y^2 or N;

ring A is a benzene ring or a 5- to 6-membered unsaturated heterocycle; a nitrogen atom present in the heterocycle may be an N-oxide; and the ring A may be substituted with one to three same or different substituents W;

Y^1 and Y^2 are each independently selected from a hydrogen atom, a halogen atom, a C_1-C_6 alkyl group, a C_2-C_6 alkenyl group, a C_1-C_6 alkoxy group, a mono- or dihydroxy C_1-C_6 alkyl group, a C_1-C_6 alkoxy C_1-C_6 alkoxy group, an amino C_1-C_6 alkoxy group, a (C_1-C_6 alkyl)amino C_1-C_6 alkoxy group, a di(C_1-C_6 alkyl)amino C_1-C_6 alkoxy group, a C_1-C_6 alkoxy C_1-C_6

alkyl group, an amino C_1-C_6 alkyl group, a (C_1-C_6 alkyl)amino C_1-C_6 alkyl group, a di(C_1-C_6 alkyl)amino C_1-C_6 alkyl group, an amino group, a (C_1-C_6 alkyl)amino group and a di(C_1-C_6 alkyl)amino group;

W is a halogen atom, a nitro group, a cyano group, a hydroxyl group, -NRaRb, -N=C(-Rc)NRaRb, -CONRaRb, -OC(=O)NRaRb, -SO_2NRaRb, -N(-Ra)C(=O)NRa'Rb', -N(-Ra)C(=O)ORd, -N[C(=O)ORd][C(=O)ORd'], -C(=O)ORd, -$S(=O)_m$-Rd, -O-Rd, -OC(=O)Rc, -N(-Ra)C(=O)Rc, -N[C(=O)Rc][C(=O)Rc'], -N(-Ra)SO_2Rc, -N(SO_2Rc)(SO_2Rc'), -C(=NORd)NRa'Rb', -C(=NRa)NRa'Rb', -C(=NORa)Rc, -C(=O)Rc, a C_1-C_6 alkyl group which may be substituted with one or more Y^3, a C_2-C_7 alkenyl group which may be substituted with one or more Y^3, a C_2-C_7 alkynyl group which may be substituted with one or more Y^3, an aryl group which may be substituted with one or more Y^3 or a heteroaryl group which may be substituted with one or more Y^3;

Ra, Ra', Rb, Rb', Rc, Rc', Rd and Rd' are each independently selected from a hydrogen atom, a C_1-C_{10} alkyl group, a C_3-C_8 cycloalkyl group, a C_2-C_8 alkenyl group, a C_2-C_8 alkynyl group, -[(C_1-C_6 alkylene)-O]$_n$-(C_1-C_3 alkyl), a tetrahydropyranyl group, a tetrahydrofuranyl group, an aryl group, a heteroaryl group, and a nitrogen-containing heterocyclyl group (wherein the nitrogen atom on the heterocyclyl group may be substituted with a

C_1-C_3 alkyl group); or

Ra and Rb, Ra' and Rb', Ra and Rd, Ra and Ra', Ra and Rc, Rc and Rc', and Rd and Ra' may form a saturated or unsaturated 5- to 6-membered heterocycle by ring-closing at the bonding position of each of these two groups and the heterocycle may be substituted with a C_1-C_6 alkyl group;

Ra, Ra', Rb, Rb', Rc, Rc', Rd and Rd' each may be substituted with one to three same or different substituents selected from Y^3;

m is an integer selected from 0 to 2;

n is an integer selected from 1 to 4;

Y^3 is a halogen atom, -NRxRy, -C(=O)ORz, -C(=O)Rz, -ORz, -C(=O)NRxRy, -OC(=O)NRxRY, -SO_2NRxRy, -N(-Rx)C(=O)NRx'Ry', -N(-Rx)C(=O)ORz, -S-Rz, -SO-Rz, -SO_2-Rz, -OC(=O)Rz, -N(Rx)C(=O)Rz, -C(=NORz)NRx'Ry', -C(=NRx)NRx'Ry', -C(=NORx)Rz, -[O-(C_1-C_6 alkylene)]$_n$-O(C_1-C_3 alkyl), -N(-Rx)-(C_1-C_6 alkylene)-O(C_1-C_3 alkyl), -C(=O)Rz, a C_1-C_6 alkyl group, a C_2-C_8 alkenyl group, a C_2-C_8 alkynyl group, an aryl group or a heteroaryl group;

Rx, Rx', Ry, Ry' and Rz are each independently selected from a hydrogen atom and a C_1-C_4 alkyl group;

Rx and Ry, Rx and Rx', Rx and Rz, and Rz and Rx' may form a saturated or unsaturated 5-to 6-membered heterocycle by ring-closing at the bonding position of each of these two groups;

a pharmaceutically acceptable salt thereof or a prodrug thereof.

2. The compound of claim 1, a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein R^2 is selected from a halogen atom, a trifluoromethyl group and a trifluoromethoxy group.

3. The compound of claim 1 or claim 2, a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein Q is a group of the formula selected from:

[Formula 3]



which may be substituted with one to three same or

different substituents W.

4. The compound of any one of claims 1 to 3, a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein Q is a group of the formula selected from: [Formula 4]



which may be substituted with one to three same or different substituents W.

5. The compound of any one of claims 1 to 4, a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein Q is a group of the formula selected from: [Formula 5]



which may be substituted with one to three same or different substituents W.

6. The compound of any one of claims 1 to 5, a pharmaceutically acceptable salt thereof or a prodrug thereof,

wherein

R^1, R^2, R^3, R^4 and R^5 are each independently selected from a hydrogen atom, a chlorine atom, a fluorine atom, a bromine atom and a trifluoromethyl group;

R^6 and R^7 are hydrogen atoms; and

Z^1 and Z^2 are each independently selected from a hydrogen atom, and a hydroxyl group.

7. The compound of any one of claims 1 to 5, a pharmaceutically acceptable salt thereof or a prodrug thereof,

wherein

R^3 and R^4 are each independently selected from a hydrogen atom, a halogen atom, a C_1-C_6 alkyl group

which may be substituted with one or more hydroxyl groups or halogen atoms, a C_1-C_6 alkoxy group which may be substituted with one or more halogen atoms, and -T-$(CH_2)_k$-V;

T is an oxygen atom or a single bond; k is an integer selected from 0 to 4;

V is a 5- to 6-menbered heterocyclyl group which may be substituted with one or more substituents selected from a hydroxy group, an amino group, C_1-C_6 alkyl group, C_1-C_6 alkoxy group and C_1-C_6 alkylcarbonyl group.

8. A compound, a pharmaceutically acceptable salt thereof or a prodrug thereof of any one of claims 1 to 7 which has Raf inhibiting effect and angiogenesis inhibiting effect and is used for treating cancer, psoriasis, atherosclerosis, chronic rheumatoid arthritis and diabetes.

9. A pharmaceutical composition comprising a compound, a pharmaceutically acceptable salt thereof or a prodrug thereof of any one of claims 1 to 7 as an active ingredient.

10. An Raf inhibitor or an angiogenesis inhibitor comprising a compound, a pharmaceutically acceptable salt thereof or a prodrug thereof of any one of claims 1 to 7 as an active ingredient.

11. A preventive or therapeutic agent for a disease selected from cancer, psoriasis, atherosclerosis, chronic rheumatoid arthritis and diabetes which comprises a compound, a pharmaceutically acceptable salt thereof or a prodrug thereof of any one of claims 1 to 7 as an active

ingredient.